Area of research
Cancer Research · Oncology
Research interest
Research focused on Breast cancer and Epirubicin, with related work in Oncology, Disease, Chemotherapy. Notable publications include 'A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease', 'OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer', and 'Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial'.
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial
A genomic approach to therapeutic target validation identifies a glucose-lowering <i>GLP1R</i> variant protective for coronary heart disease
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study
Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial
Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial